Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer

Early response to neoadjuvant iFAC predicted favorable prognosis in breast cancer

"The aim of this study was to evaluate the efficacy and safety of neoadjuvant chemotherapy with iFAC in locally advanced breast cancer (LABC). Eighty-two LABC patients were treated with neoadjuvant iFAC chemotherapy including infusional 5-FU (1000 mg/m², continuous intravenous infusion, days 1-3), adriamycin (40 mg/m², intravenous bolus, day 1) and cyclophosphamide (600 mg/m², intravenous bolus, day 1) every 3 weeks until maximum tumor response," scientists in South Korea reported.

...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications